Aurinia publishes corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plans

Reuters2026/08/06 12:28

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aurinia highlighted continued commercial growth for lupus nephritis drug LUPKYNIS.
Six months ended June 30, 2026: total revenue USD 160.9 million; net income USD 71.8 million; operating cash flow USD 85.1 million.
2026 guidance: total revenue USD 315 million to USD 325 million; net product sales USD 305 million to USD 315 million.
Pipeline focus included advancing aritinercept development in autoimmune disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aurinia publishes corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plans

You may also like

Crypto prices